HighVista Strategies LLC Has $1.34 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

HighVista Strategies LLC cut its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 40.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 126,741 shares of the company’s stock after selling 85,377 shares during the quarter. HighVista Strategies LLC’s holdings in Roivant Sciences were worth $1,340,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ROIV. ProShare Advisors LLC lifted its stake in shares of Roivant Sciences by 9.0% in the second quarter. ProShare Advisors LLC now owns 61,582 shares of the company’s stock worth $651,000 after acquiring an additional 5,108 shares during the period. Profund Advisors LLC raised its holdings in Roivant Sciences by 10.1% during the 2nd quarter. Profund Advisors LLC now owns 156,724 shares of the company’s stock worth $1,657,000 after purchasing an additional 14,377 shares during the last quarter. Rubric Capital Management LP lifted its position in shares of Roivant Sciences by 15.0% in the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock worth $243,110,000 after purchasing an additional 3,000,000 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Roivant Sciences by 119.9% in the 2nd quarter. Thrivent Financial for Lutherans now owns 186,051 shares of the company’s stock valued at $1,966,000 after purchasing an additional 101,437 shares during the last quarter. Finally, Sei Investments Co. raised its stake in Roivant Sciences by 64.3% during the second quarter. Sei Investments Co. now owns 22,151 shares of the company’s stock worth $234,000 after buying an additional 8,667 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Up 0.4 %

Shares of NASDAQ ROIV opened at $11.97 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. The company has a 50-day moving average price of $11.46 and a 200-day moving average price of $11.05. The stock has a market capitalization of $8.84 billion, a P/E ratio of 2.37 and a beta of 1.25. Roivant Sciences Ltd. has a 1 year low of $8.24 and a 1 year high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The firm had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. During the same period in the previous year, the company posted ($0.38) EPS. The company’s revenue for the quarter was up 155.1% on a year-over-year basis. On average, equities research analysts forecast that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ROIV has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Thursday. Piper Sandler raised their target price on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Bank of America boosted their price target on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $17.39.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.